Efficacy of Micro-excisional Skin Removal by Micro-coring Device in Treatment of Wrinkles and Laxity of Face and Neck

Inclusion Criteria: * Fitzpatrick Skin Type 1, 2, or 3 as judged by the Investigator * Two or more of the following: Facial wrinkles assessed using the Lemperle Wrinkle Assessment Scale (descriptive and pictorial) * Cheek fold lines \>2 * Upper lip lines \>3 * Nasolabial Folds \>3 * Marionette lines \>3 * Labiomental crease \>3 * Corner of the mouth lines \>3 * Periocular lines \>3 * Able to provide written informed consent, understand and willing to comply with all study related directions from investigator and follow-up visits. Exclusion Criteria: * Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be treated * History of keloid formation or hypertrophic scarring * History of trauma or surgery to the treatment areas in the past 6 months * Scar present in the areas to be treated * Silicone or synthetic material injections in the areas to be treated * Injection of FDA-approved dermal fillers in the past two years * Injection of fat in the past year * History of treatment with dermabrasion, ablative laser, or radiofrequency in the past year * History of treatment with non-ablative laser in the past 6 months * History of treatment with botulinum toxin injections in the areas to be treated within the prior 6 months * Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment * Active, chronic, or recurrent infection * History of compromised immune system or currently being treated with immunosuppressive agents * History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine * Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment * Treatment with aspirin or other blood thinning agents within 14 days prior to treatment * History or presence of any clinically significant bleeding disorder * Co-morbid condition that in the Investigator's opinion could limit ability to participate in the study or to comply with follow-up requirements * History of drug and/or alcohol abuse * Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or give informed consent * Treatment with an investigational device or agent within 30 days before treatment or during the study period